RE:RE:Numbers show Canopy Growth struggles in every market CGC’s net revenue has increased 37.1% year-over-year to CAD546.65 million ($436.38 million) in its fiscal year ended March 31, 2021. However, the company’s loss from operations came in at CAD1.24 billion ($992.56 million), and its net loss amounted to CAD1.74 billion ($1.39 billion). Its comprehensive loss rose 82.7% year-over-year to CAD2.0 billion ($1.6 billion).
The stock has declined 23.7% year-to-date and 54.9% over the past six months. And it is currently trading 66.8% below its 52-week high of $56.50, indicating short-term bearishness.
CGC’s POWR Ratings are consistent with this bleak outlook. The stock has an overall F rating, which translates to a Strong Sell in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
CGC has a C grade for Growth, D for Stability, and an F for Value. Of the 220-stocks in the F-rated Medical – Pharmaceuticals industry, it is ranked #218.
In addition to the POWR Ratings grades we’ve just highlighted, one can see the CGC ratings for Stability, Momentum, and Sentiment.